Mounjaro is the most under-discussed thing on this board
Thinking out loud about this: Mounjaro is the most under-discussed thing on this board.
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Removed the conversion table. There is no published equivalence between the two molecules and posting one as fact is exactly the kind of thing that gets copied for years.
2.5 is the starter dose and it is not meant to be the dose that works
2.5 is the starter dose and it is not meant to be the dose that works
Saving this one. It is the clearest statement of the stall problem I have read here.
Are you comparing yourself with the trial mean or with the people who post the most?
switching from sema is not a dose conversion, there is no clean equivalence
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.